ObjectiveTo summarize the common imaging features of liver cancer after local-regional therapy in order to more accurately evaluate the post-treatment response of it. MethodThe literatures of studies on imaging features after ablation, transcatheter therapy, and radiotherapy of liver cancer in recent years were searched and reviewed. ResultsIt was not accurate to evaluate the response of liver cancer after treatment only by comparing the size of tumor before and after treatment. We should follow up and observe the changes of enhancement components after tumor treatment, and pay attention to identify the normal features after treatment. ConclusionsImaging evaluation after local-regional therapy of liver cancer is of great significance in management and clinical decision-making of patients with liver cancer. Standard response evaluation systems such as EASL or mRECIST should be carefully applied after local-regional therapy of liver cancer. Treatment response of patients should be comprehensively evaluated in combination with the characteristics of local-regional therapy methods and timing, so as to avoid delaying timing of secondary treatment and causing excessive treatment.
Liver cancer is a highly prevalent malignancy of the digestive system in China. Hepatic imaging examinations, including CT and MRI, play a critical role in the screening, diagnosis, and therapeutic evaluation of liver cancer. To standardize terminology, reduce variability in imaging interpretation, and improve diagnostic consistency and accuracy, the Department of Radiology of West China Hospital of Sichuan University has developed a structured hepatic imaging report specifically designed for high-risk populations of primary liver cancer. This system is based on the 2018 version of the Liver Imaging Reporting and Data System published by the American College of Radiology. We introduce the design background, core elements, and practical application experience of the structured hepatic imaging report system developed by West China Hospital of Sichuan University, aiming to promote the standardization and uniformity of hepatic imaging evaluation for high-risk populations of liver cancer.